Sign in

Pete Lucas

Research Analyst at CJS Securities

Pete Lucas is an Analyst at CJS Securities specializing in equity research, with a focus on companies in industries such as auto auctions and healthcare. He has contributed to coverage of companies like ACV Auctions and Invacare, regularly participating in major earnings calls and investor analyses. Lucas has been with CJS Securities since at least 2022, having established a track record of insightful questioning and sector-specific diligence, though quantifiable performance metrics and prior career history remain undisclosed in public records. His professional credentials, including any FINRA registrations or securities licenses, are not publicly available.

Pete Lucas's questions to Lantheus Holdings (LNTH) leadership

Question · Q3 2025

Pete Lucas asked for more details on the competitive landscape within the Alzheimer's imaging market, particularly for tau tangle imaging, and how MK-6240 is positioned against other products.

Answer

CEO Brian Markison described MK-6240 as a second-generation tau agent with demonstrated superiority in studies compared to commercially available options like Talvet. He emphasized the increasing importance of tau imaging for staging and longitudinal management of Alzheimer's disease.

Ask follow-up questions

Question · Q3 2025

Pete Lucas asked for more color on the competitive landscape in the Alzheimer's imaging market, specifically on the tau tangle side, and how MK-6240 is positioned against other products.

Answer

Brian Markison, CEO, described MK-6240 as a second-generation tau agent, highlighting its reported superiority in head-to-head studies compared to commercially available agents like Talvet, and emphasized tau's increasing importance in staging and longitudinal management of Alzheimer's disease.

Ask follow-up questions

Pete Lucas's questions to Stevanato Group S.p.A. (STVN) leadership

Question · Q4 2024

Pete Lucas of CJS Securities, on behalf of Larry Solow, asked about the recovery path for the Engineering segment's operating margins and their potential to return to and exceed mid-teens levels.

Answer

CFO Marco Dal Lago confirmed progress, with the segment reaching a 15.3% operating margin in Q4, and stated the goal is to resolve project delays by mid-2025. Chairman and CEO Franco Stevanato added that beyond fixing delays, the company is optimizing the segment's cost structure and footprint to improve efficiency and capture future growth in biologics.

Ask follow-up questions

Pete Lucas's questions to HEICO (HEI) leadership

Question · Q1 2025

Pete Lucas inquired about the drivers of the Flight Support Group's strong organic growth, asking if it stemmed from deeper penetration with existing customers or expansion to new ones, and questioned the outlook for the segment's high operating margins.

Answer

Eric Mendelson, Co-President, confirmed that growth is primarily from deeper market penetration with existing customers who desire more cost-saving solutions. Regarding margins, he expressed reluctance to forecast increases beyond the current 26% EBITA level, despite a consistent upward trend, attributing success to an experienced, efficient team rather than aggressive pricing.

Ask follow-up questions

Best AI for Equity Research

Performance on expert-authored financial analysis tasks

Fintool-v490%
Claude Sonnet 4.555.3%
o348.3%
GPT 546.9%
Grok 440.3%
Qwen 3 Max32.7%